OraSure woes
This article was originally published in The Gray Sheet
Executive Summary
A Los Angeles clinic says it will stop using the OraQuick Advance rapid oral HIV test due to a number of false positive test results, which caused the firm's stock price to drop over 20% Dec. 16 from a Dec. 15 close of $11.37. Similar false positive results from clinics in New York and San Francisco have also been reported. The firm is working with health departments where the false results were reported, but stressed that the test is intended as an initial screening device and that labeling instructs those with positive results to seek further testing. OraSure received another blow Dec. 14 when the House approved a measure stripping language from the HHS appropriations bill that would have directed HHS to buy one million rapid oral HIV tests...
You may also be interested in...
OraSure Studying “Site-Specific Factors” Behind Flawed HIV Test Results
OraSure is conducting an investigation of its OraQuick Advance rapid oral HIV test due to concerns about the test's reliability, the company said Dec. 20
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.